Correspondence 0001683168-23-009065 from Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp.
Date: Dec. 22, 2023 · CIK: 0001533040 · Accession: 0001683168-23-009065
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276146
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Registration Statement on Form S-1 Filed December 19, 2023 File No. 333-276146 Request for Acceleration of Effective Date
Dear Mr. Crawford:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on December 27, 2023, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Brandon Kinnard of Hogan Lovells US LLP at (303) 454-2477. Also, please notify Mr. Kinnard when this request for acceleration has been granted.
Very truly yours,
PHIO PHARMACEUTICALS CORP.
Show Raw Text
CORRESP 1 filename1.htm PHIO PHARMACEUTICALS CORP. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 December 22, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed December 19, 2023 File No. 333-276146 Request for Acceleration of Effective Date Dear Mr. Crawford: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on December 27, 2023, or as soon thereafter as possible. Please direct any questions or comments concerning this request to Brandon Kinnard of Hogan Lovells US LLP at (303) 454-2477. Also, please notify Mr. Kinnard when this request for acceleration has been granted. Very truly yours, PHIO PHARMACEUTICALS CORP. By: /s/ Robert J. Bitterman Name: Robert J. Bitterman Title: President and Chief Financial Officer